TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a ...

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...

On Monday, June 1, Antibe Therapeutics announced the positive top-line data from the phase 2B dose-ranging, efficacy study of their lead drug candidate ATB-346. However, the stock closed 25% down.

On Monday June 1, Antibe Therapeutics announced the top-line data from the phase 2B dose-ranging, efficacy study of their lead drug candidate ATB-346. According to the company, ATB-346 'met the ...

Worldcategory Mpox virus detected in Pakistan, health authorities say 8:04 AM UTC · Updated ago Public Healthcategory Bavarian Nordic seeks EU approval to extend mpox vaccine to adolescents 6:54 ...

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Antibe Therapeutics Inc. (“Antibe” or the “Company”) announced that, in connection with its previously announced receivership proceedings ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Antibe Therapeutics (TSE:ATE) ...

Antibe Therapeutics is seeking to fill a vast market void with a “ground-breaking” class of painkiller drugs. While the journey bringing the drug to market may be long and arduous, the end result ...

Antibe Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports ...

About Antibe Therapeutics Inc. Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target ...

But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? So should Antibe Therapeutics (TSE:ATE) shareholders be worried about its cash burn? In this ...